BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.
about
Ethnic background and genetic variation in the evaluation of cancer risk: a systematic reviewBRCAness: finding the Achilles heel in ovarian cancerOlaparib in the management of ovarian cancerThe expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2Autophagy and cancer cell metabolismAssociation between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.Cancer's Achilles' Heel: Apoptosis and Necroptosis to the RescueTumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155Micronuclei in genotoxicity assessment: from genetics to epigenetics and beyondThe Werner's Syndrome RecQ helicase/exonuclease at the nexus of cancer and agingHomologs of breast cancer genes in plantsSubstitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group studySite-specific phosphorylation of the DNA damage response mediator rad9 by cyclin-dependent kinases regulates activation of checkpoint kinase 1Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsCommon genetic variants and modification of penetrance of BRCA2-associated breast cancerPI 3 kinase related kinases-independent proteolysis of BRCA1 regulates Rad51 recruitment during genotoxic stress in human cells.Development and validation of a variant detection workflow for BRCA1 and BRCA2 genes and its clinical application based on the Ion Torrent technology.Mutations in BRCA2 and taxane resistance in prostate cancerRapid evolution of BRCA1 and BRCA2 in humans and other primates.Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells.Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.BRCA2 is a mediator of RAD51- and DMC1-facilitated homologous recombination in Arabidopsis thaliana.BRCC36A is epistatic to BRCA1 in DNA crosslink repair and homologous recombination in Arabidopsis thalianaConnection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA RepairRare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complexGrowing recognition of the role for rare missense substitutions in breast cancer susceptibilityDetoxification: a novel function of BRCA1 in tumor suppression?HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.Modern reproductive patterns associated with estrogen receptor positive but not negative breast cancer susceptibilityThe inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancerIn Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein.Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation CarriersAssociation of BRCA1 functional single nucleotide polymorphisms with risk of differentiated thyroid carcinoma.Integrated sequence and expression analysis of ovarian cancer structural variants underscores the importance of gene fusion regulationBi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis.Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ.Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.
P2860
Q24288685-2DDB5B26-9532-4E97-BD6E-F1F72FB38246Q24630872-EDE904BE-5F21-433A-85C6-A5EF6508E727Q26797166-C3A9F268-C7B2-4118-87D0-CBFA3A1BEB1AQ26851138-079A5458-9664-4E77-AC12-EB70E2BE66C8Q27022418-DE9A0214-6D47-4755-B9B2-894FAE96FC69Q27851709-3C26E280-4B93-4EAF-9077-316C08BF901EQ28066868-EC5D47EA-B99A-4C9F-B6CA-CFC3B29DBBEDQ28249114-E36A778B-EE96-4ACE-A52C-E6494DF714AFQ28294979-73C82D26-48E7-49D4-9FAB-92DBCBA40306Q28306378-A05CF68A-415C-4102-880D-A2CE51CF09FEQ28729894-CBBCB01F-B2DC-49AD-BE76-13009C7208DBQ30395158-9AD59786-575F-4BF1-BFDF-E4CF1764DC32Q30419554-86B17D37-8853-4F34-98E1-5BB537D2EF39Q30419946-B2D0127A-D45C-4E41-90A9-102E4506B724Q33458308-13CE9A7E-B4B5-40F0-921F-1930EB237908Q33618910-C5811542-D0CC-436B-AC4A-54930605F0AEQ33742096-DA251150-26E2-48A9-8397-10320D64BDD7Q33754568-8F418A83-8783-4348-AFF8-D789E8826AEFQ33836680-2A50C8FA-1939-4913-9EF4-A0E8B2F8D3BEQ33870601-20E09DA4-32C7-4A03-A694-47AA895AD8A1Q33930642-BB205433-4573-4724-9A50-D33D09D10005Q34155349-2ADFC86E-4D82-4C67-9E8E-1121FD48D834Q34199816-2A37F847-E830-46F0-AA1C-060A47309820Q34231923-5B681DB4-C2CD-4A2E-BC83-0EFBC9DB6974Q34474044-C5E9128B-9B54-45AD-8F0E-317EA7C9AD54Q34481443-F96CD7A5-6B50-42BA-A585-350CBDD30F0DQ34621039-6B9B39CD-E701-450B-A5C1-6A797C1A8CD4Q35081354-9D598A92-35CB-4024-9BCB-1CFFCBDFEC14Q35106767-0319076D-BB12-442A-AEBB-1458B7268910Q35127699-FB00368F-968F-4C91-8D57-2BCB2AD9579FQ35175294-B4E716BE-B5C5-4675-88FE-0727428A4A51Q35184055-8A5F3AD3-45F2-4965-B41C-C2A8AE5E4A48Q35238263-9174EDFE-4AB5-40CD-8557-4E22755BE31AQ35440379-12FA8F9A-08EF-4A32-B930-BB68BCFFB260Q35679122-DD37D07C-1BEA-4435-8DFE-7C6D63A60794Q35686579-31A5C08B-B1DB-462A-9B86-EA782838D053Q35692785-900D27D2-6780-4C20-BC96-4B909B8089D3Q35737313-DB59A6AF-45E0-41D8-AB01-F82C9D31D23EQ35879098-D0A1CDC7-D6AE-46CD-9467-55EF2BF272EBQ35914568-B0B67F4D-AAF7-4794-B93C-1F6FF99989D5
P2860
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BRCA1 and BRCA2: breast/ovaria ...... NA double-strand break repair.
@ast
BRCA1 and BRCA2: breast/ovaria ...... NA double-strand break repair.
@en
BRCA1 and BRCA2: breast/ovaria ...... NA double-strand break repair.
@nl
type
label
BRCA1 and BRCA2: breast/ovaria ...... NA double-strand break repair.
@ast
BRCA1 and BRCA2: breast/ovaria ...... NA double-strand break repair.
@en
BRCA1 and BRCA2: breast/ovaria ...... NA double-strand break repair.
@nl
prefLabel
BRCA1 and BRCA2: breast/ovaria ...... NA double-strand break repair.
@ast
BRCA1 and BRCA2: breast/ovaria ...... NA double-strand break repair.
@en
BRCA1 and BRCA2: breast/ovaria ...... NA double-strand break repair.
@nl
P2860
P356
P1433
P1476
BRCA1 and BRCA2: breast/ovaria ...... NA double-strand break repair.
@en
P2093
David M Livingston
Peter J O'Donovan
P2860
P304
P356
10.1093/CARCIN/BGQ069
P407
P577
2010-04-16T00:00:00Z